Search results
Results from the WOW.Com Content Network
The Global Plan to End TB, 2023-2030 [6] is a plan for ending TB as a public health challenge by 2030. It is produced by the Stop TB partnership and provides a blueprint of priority actions required and a detailed estimate of financial resources needed to end TB.
The patent was supposed to expire in July 2023, but J&J's evergreening practices will not allow the distribution of generics in several countries heavily afflicted by tuberculosis. [ 31 ] In July 2023, the WHO's Stop TB program and Johnson & Johnson came to an agreement allowing for Stop TB Partnership's Global Drug Facility to produce generic ...
[7] [8] In October 2023 she assumed the chair of the Tuberculosis Research Network from the World Health Organization, a United Nations organization. [9] [10] In February 2024, she hosted the Stop TB Partnership in Brazil, alongside WHO's director Tedros Adhanom.
The World Health Organization (WHO) declared TB a "global health emergency" in 1993, [14] and in 2006, the Stop TB Partnership developed a Global Plan to Stop Tuberculosis that aimed to save 14 million lives between its launch and 2015. [132]
The WHO as well as the Stop TB Partnership aim for the full elimination of TB by 2050—requiring a 1000-fold reduction in tuberculosis incidence. [3] As of 2017, tuberculosis has not been eliminated from any country.
Stop TB Partnership; T. TB Alliance; Tibetan Delek Hospital; ... This page was last edited on 10 January 2023, at 19:53 (UTC).
Eva Longoria declared that Kamala Harris’ success is “our success” before sharing a version of an iconic campaign slogan for the vice president’s 2024 bid ahead of Harris’ speech at the ...
Johnson & Johnson announced 2023 that it did not intend to enforce its patents bedaquiline for the treatment of multidrug-resistant TB in 134 LMIC countries. [39] Johnson & Johnson also granted Stop TB Partnership´s Global Drug Facility`s a license that enabled the tender, procurement and supply of generic versions of bedaquiline. [40]